Related Experiment Video
Updated: Aug 17, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Investigational strategies in chronic myelogenous leukemia
Jorge E Cortes1, Susan M O'Brien, Francis Giles
1Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. jcortes@mdanderson.org
Abstract:
Imatinib is the cornerstone of therapy in chronic myelogenous leukemia (CML) and a model for the development of novel agents directed at specific targets. The results of imatinib therapy continue to improve with approaches such as higher doses of imatinib and, possibly, with combinations of imatinib and interferon-alpha with or without cytarabine. There are multiple targets with agents directed to them that may prove to be synergistic with imatinib. These approaches are attractive, particularly when dealing with imatinib resistant CML, to prevent resistance and improve the probability of cure. The continued understanding of the biology of CML and mechanisms of resistance to imatinib and the ability to develop target-specific therapies should lead to the increased probability of cure for most patients who have CML.
Insights
Imatinib therapy for chronic myelogenous leukemia (CML) is improving with higher doses and combination treatments. New targeted therapies aim to overcome imatinib resistance and increase cure rates for CML patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Imatinib is a primary treatment for chronic myelogenous leukemia (CML).
- Novel targeted therapies are emerging as crucial in cancer treatment.
- Understanding CML biology and imatinib resistance is key to improving outcomes.
Purpose of the Study:
- To review current and emerging therapeutic strategies for chronic myelogenous leukemia (CML).
- To explore the role of imatinib, its combinations, and novel targeted agents in CML treatment.
- To discuss approaches for overcoming imatinib resistance and enhancing cure probability.
Main Methods:
- Review of current literature on imatinib therapy in CML.
- Analysis of emerging treatment strategies including higher imatinib doses and combination therapies.
- Exploration of targeted agents and their potential synergy with imatinib.
Main Results:
- Imatinib therapy outcomes continue to improve with optimized dosing and combinations.
- Interferon-alpha and cytarabine combinations show potential with imatinib.
- Multiple targeted agents may offer synergistic effects with imatinib, especially in resistant cases.
Conclusions:
- Optimizing imatinib therapy and exploring combinations are vital for improving CML treatment.
- Targeted therapies hold promise for overcoming imatinib resistance and increasing cure rates.
- Continued research into CML biology and resistance mechanisms will enhance patient prognoses.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
